Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
increase » increased (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
increase » increased (Expand Search)
-
2721
-
2722
-
2723
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
2724
-
2725
-
2726
-
2727
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
2728
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
2729
-
2730
-
2731
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
2732
-
2733
-
2734
-
2735
-
2736
-
2737
-
2738
-
2739
-
2740
Molecular docking showed that ABT-199 can fit into active site of ALK<sup>Mutant</sup>.
Published 2025Subjects: